
Novo Nordisk says obesity pill leads to 15% weight loss; availability ‘to be determined’
By Deena Beasley SAN DIEGO (Reuters) – Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills. Novo plans to seek U.S. and European…